Walgreens Inks Multi-Year Pact With Freenome To Advance Blood-Based Tests For Early Cancer Detection

Walgreens Boots Alliance, Inc. WBA entered into a multi-year relationship with Freenome to advance clinical studies of blood-based tests for early cancer detection.

Under the deal, Walgreens plans to merge its national footprint, patient insights, compliant recruitment technology, and local infrastructure to Freenome's multi-cancer research program.

Walgreens and Freenome will also work together on building risk-prediction models and population health software. 

Also Read: Walgreens Boots Sells Remaining Stake In Option Care Health For $330M

Working with technology provider Curebase, Walgreens will initially recruit patients across diverse populations for Freenome's Sanderson Study, which aims to evaluate blood-based early detection tests.

The Sanderson Study will enroll approximately 8,000 participants through its clinical study partner network, which includes Walgreens.

Using Curebase's platform, Walgreens will deliver targeted outreach to potentially eligible patients and caregivers of all backgrounds by performing a single blood draw at one of the company's clinical trial locations.

Price Action: WBA shares are trading lower by 0.33% to $31.92 on the last check Friday.